Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics operates as a clinical-stage biotechnology company developing viral immunotherapy platforms for solid tumor treatment. The company's news coverage centers on clinical trial developments, regulatory interactions, financing activities, and leadership appointments that shape its path toward potential commercialization of novel cancer therapies.
For biotechnology investors, Candel's news flow typically includes updates on clinical trial enrollments, interim data readouts, and final study results that determine whether investigational therapies advance through development stages. Regulatory milestones such as FDA designations, EMA opinions, and clinical trial authorizations signal progress through the complex approval process for novel oncology treatments. The company also announces financing transactions including registered offerings, term loan agreements, and strategic partnerships that fund ongoing research programs.
This news resource provides coverage of material events disclosed through SEC filings, corporate press releases, and regulatory databases. Expect updates on Phase 2 and Phase 3 trial results, orphan drug designations, breakthrough therapy evaluations, and scientific presentations at oncology conferences. Leadership changes, including appointments of executives with immunotherapy expertise and clinical development experience, often indicate strategic shifts in the company's development priorities.
Tracking Candel Therapeutics news helps investors monitor the progress of specific drug candidates through clinical validation, understand capital allocation decisions, and assess the company's competitive position within the viral immunotherapy sector. Bookmark this page for updates on trial outcomes, regulatory decisions, and corporate developments that influence the company's trajectory.
Candel Therapeutics announced on April 17, 2023, that the FDA has granted fast track designation for its investigational viral immunotherapy CAN-2409 combined with valacyclovir and pembrolizumab. This designation aims to expedite the drug's development for patients with late-stage non-small cell lung cancer (NSCLC) resistant to first-line therapies. CAN-2409 targets patients without molecular driver mutations and aims to enhance survival rates and delay disease progression. Clinical trial data revealed a 77% disease control rate in a subset of patients with previous treatment failures. The company plans to present updated data from the ongoing Phase 2 trial in the third quarter of 2023, showcasing the potential of CAN-2409 in treating various solid tumors.
Candel Therapeutics, Inc. (Nasdaq: CADL) reported financial results for Q4 and FY 2022, showcasing promising advancements in its viral immunotherapy programs. The company extended its cash runway into Q2 2024 with cash and equivalents of $70.1 million, down from $82.6 million in 2021. Notably, CAN-2409 demonstrated a 77% disease control rate in non-small cell lung cancer patients. Candel anticipates multiple clinical data readouts in 2023, including topline results from its prostate cancer trial in Q4 2024. Despite a net loss of $5.1 million for Q4 2022, the company's strategic partnerships and ongoing trials bolster its potential to innovate cancer treatments.
Candel Therapeutics (Nasdaq: CADL) announced that CEO Paul Peter Tak will participate in a fireside chat at the Guggenheim 2023 Healthcare Talks Oncology Day on February 8, 2023, at 3:20 p.m. EST. This event will occur at the St. Regis Hotel in New York City. A live webcast can be accessed under the 'Events and Presentations' section on Candel's website, with a replay available for 30 days after the event.
Candel is focused on developing novel viral immunotherapies to treat cancer, utilizing genetically modified adenovirus and herpes simplex virus platforms. Their lead candidates are CAN-2409 and CAN-3110.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
